Merck’s Keytruda (pembrolizumab) Receives FDA’s Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)

 Merck’s Keytruda (pembrolizumab) Receives FDA’s Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)

Merck’s Keytruda (pembrolizumab) Receives FDA’s Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)

Shots:

  • The approval is based on P-III KEYNOTE-042 trial results assessing Keytruda (200mg, q3w) vs CT in 1274 patients in ratio (1:1) with 1L stage III whose tumors expressed PD-L1 with TPS ≥1% and who had not received prior systemic treatment for metastatic NSCLC
  • P-III KEYNOTE-042 study results: @ TPS ≥1%, TPS ≥50% mOS (16.7, 20.0 vs 12.1, 12.2mos.); mPFS (5.4, 7.1 vs 6.5, 6.4mos.); DOR @≥12mos., ≥18 mos. (47%, 42% vs 16%, 17%), (26%, 25% vs 6%, 5%); ORR (27%, 39% vs 27%, 32%)  
  • Keytruda (pembrolizumab) 100mg is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2 and is evaluated in 900 trial globally in oncology

Click here to read full press release/ article | Ref: Merck & Co | Image: BioWorld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post